Benefits from ustekinumab treatment were maintained through week 100, according to a study of 615 adult patients with active psoriatic arthritis (PsA) who were randomized to receive placebo or either of 2 ustekinumab dosages. Researchers found:

• At week 100:

• 56.7% to 63.6% of patients achieved a ≥ 20% improvement in ACR20 score.

• 71.9% to 76.7% of patients achieved a moderate/good score in DAS28-CRP score.

• 63.9% to 72.5% of patients achieved a ≥ 75% improvement in PASI75 score.

• The median percent improvement in dactylitis and enthesitis was 100.

• In the usetekinumab groups, the mean changes in vdH-S score from weeks 52-100 were similar to those seen in weeks 0 to 52.

• Through week 108, 70.7% of patients had an adverse event and 9.7% had a serious adverse event.

Citation: Feldman CH, Yzdany J, Guan H, Solomon DH, Costenbader KH. Maintenance of clinical efficacy and radiographic benefit through 2 years of ustekinumab therapy in patients with active psoriatic arthritis: Results from the PSUMMIT 1 trial. [Published online ahead of print June 19, 2015]. Arthritis Care Res. 10.1002/acr.22636.